/
Nephrology
Renal Impairment
15
Pipeline Programs↗
17
Active Trials↗
93
Companies Involved↗
Renal Impairment is an emerging landscape with 15 programs across 93 companies. The most active players are Gan & Lee Pharmaceuticals., Vincentage Pharma Co., Ltd, Rigerna Therapeutics Co., Ltd.; Rigerna Therapeutics (Beijing) Co., Ltd..
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical
No programs
Phase 115
Phase 2
No programs
Phase 3
No programs
Approved
No programs
Analysis
Trial Status
267
clinical trials
Completed228 · 85%
Terminated16 · 6%
Recruiting11 · 4%
Not yet recruiting5 · 2%
Unknown status5 · 2%
Active, not recruiting1 · 0%
Other1 · 0%
Clinical Trials
Trial Activity
267 trials
Page 1 of 18
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)